Anzeige
Mehr »
Freitag, 03.10.2025 - Börsentäglich über 12.000 News
Golden Cross macht sich bereit: 1.350 Goldabbaustellen, 55 Ladder-Ziele und ein historischer Volltreffer
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40MF2 | ISIN: US7574683014 | Ticker-Symbol: 2RH
NASDAQ
02.10.25 | 21:55
2,200 US-Dollar
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
REDHILL BIOPHARMA LTD ADR Chart 1 Jahr
5-Tage-Chart
REDHILL BIOPHARMA LTD ADR 5-Tage-Chart

Aktuelle News zur REDHILL BIOPHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoRedHill Biopharma stock surges after court upholds $10M judgment25
05.09.RedHill Biopharma Ltd. H1 Earnings Summary21
05.09.RedHill Biopharma Ltd. - 6-K, Report of foreign issuer15
05.09.RedHill Biopharma Ltd.: RedHill Biopharma Announces First Half 2025 Financial Results and Operational Highlights151Extensive strategic, financial and operational overhaul has reshaped and refocused our business; Strong progress on multiple fronts Commercial and R&D Highlights: ...
► Artikel lesen
14.08.RedHill Biopharma Ltd. - 6-K, Report of foreign issuer8
21.07.Redhill Biopharma stock soars after FDA provides positive pathway for Crohn's drug38
21.07.RedHill Biopharma Ltd. - 6-K, Report of foreign issuer7
21.07.RedHill Biopharma Ltd.: RedHill Receives Positive FDA Feedback on Pathway to Approval of Groundbreaking RHB-204 for Crohn's Disease226The positive FDA feedback allows for: A novel Phase 2 RHB-204[1] study, planned to be the first ever clinical study in a specifically defined Mycobacterium avium...
► Artikel lesen
REDHILL BIOPHARMA Aktie jetzt für 0€ handeln
01.07.RedHill Biopharma Ltd.: RedHill Biopharma Announces Recruitment Initiated into Expanded Phase 2 Opaganib/Darolutamide Combination Study in Advanced Prostate Cancer330Recruitment initiated into the Phase 2 opaganib plus darolutamide study in patients with advanced prostate cancer, sponsored by ANZUP, and supported by Bayer and...
► Artikel lesen
25.06.RedHill Biopharma Ltd. - F-1, Registration statement for certain foreign private issuers11
25.06.RedHill Biopharma Ltd. - 6-K, Report of foreign issuer3
27.05.RedHill Biopharma Ltd. - 6-K, Report of foreign issuer22
13.05.RedHill Biopharma Ltd. - 6-K, Report of foreign issuer3
05.05.RedHill Biopharma Ltd. - 6-K, Report of foreign issuer5
28.04.RedHill Biopharma Ltd. - 6-K, Report of foreign issuer12
17.04.RedHill Biopharma steht vor Compliance-Problemen mit der NASDAQ39
17.04.RedHill Biopharma faces Nasdaq non-compliance issue3
17.04.RedHill Biopharma receives Nasdaq letter over minimum stockholders' equity deficiency2
17.04.RedHill Biopharma Ltd.: RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency269The Notification Letter has no immediate effect on the Company's listing on the Nasdaq Capital Market at this time, nor are the Company's business operations affected...
► Artikel lesen
16.04.RedHill Biopharma Ltd. - 6-K, Report of foreign issuer2
Weiter >>
25 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,3